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A B S T R A C T
The definitive cure for human immunodeficiency virus type-1 (HIV) infection is represented by the eradication of
the virus from the patient’s body. To reach this result, cells that are infected but do not produce the virus must
become recognizable to be killed by the immune system. For this purpose, drugs defined “latency reverting
agents” (LRA) that reactivate viral production are under investigation. A few clinical studies have been per-
formed in HIV-infected patients treated with LRA and combined antiretroviral therapy (cART). The strategy is
thus to combine cART and LRA to reactivate the virus and unmask latently infected cells that, because of cART,
cannot produce a fully competent form of the virus. Unmasked cells can present viral antigens to the immune
system, that ultimately recognizes and kills such latently infected cells. This review reports and discusses recent
studies that have been published on this topic.
1. Introduction
Combined antiretroviral therapy (cART) controls replication of the
human immunodeficiency virus type-1 (HIV) by affecting different
stages of the viral life cycle, including cell entry, reverse transcription,
integration, and assembling of the virion [1]. The use of cART has led to
a prolongation of the lifespan of HIV-positive individuals lifespan and
to an improvement in the quality of life, turning the concept of HIV
infection as a life-threatening disease into a chronic infectious disease
[2,3], characterized by a persistent activation of the immune system
[4].
Even if cART puts a harness on viral replication and decreases
plasma viremia in most treated patients [5,6], it is unable to completely
eliminate infected cells. Thus, the presence of resting, memory CD4+ T
cells carrying proviral DNA remains a major obstacle for HIV eradica-
tion because, once re-activated, these latently infected cells are a po-
tential source of viruses [7,8]. The genome of HIV integrates into the
host DNA but cannot express itself significantly, because the activation
of the proviral promoter long terminal repeat (LTR) requires the in-
tervention of several cellular transcription factors. In the absence of
adequate stimuli, these latent reservoirs are stable and resistant to
different treatment regimens [9–12]. As respects, discovering in-
tegrated virus from the host’s genome and accordingly target infected
but not virus-producing cells is remarkably challenging.
The immune system cannot recognize latently infected cells, and
such cells escape from both the attack of the immune system, and are
not touched by cART [1]. There are two main strategies for trying to
eradicate the infection, of for its cure, that include “sterilizing cure” and
“functional cure”. The sterilizing cure include treatments such as stem
cell transplantation, genome editing, gene therapy and “shock and kill”
strategy [13–15]. On the other hand, functional cure implies the long-
term control of viral replication with the aim of preserving a normal
CD4+ T cell count and undetectable level of viral replication [16].
In the last years, promising studies have identified drugs which are
able to reverse latency without activating T cells and causing the pro-
duction of new virions [17–19]. The aim of this strategy is to combine
latency reverting agents (LRA) with cART so that LRA can activate the
production of the virus by latentely infected cells: viral peptides are
presented to the immune system that finally can recognize and kill
infected cells. However, because of the presence of protease inhibitors
among the drugs used in the cART, in theory the complete form of the
virion does not have be produced, and thus viral load has to remain
undetectable.
LRA include disulfiram and the histone deacetylase (HDAC) in-
hibitors, such as vorinostat (suberoylanilide hydroxamic acid or SAHA)
[20–22]. The molecular mechanism of latency reactivation induced by
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disulfiram is unclear [23]. The role of HDAC is to remodel chromatin
during transcription, leading to the prevention of LTR promoter ex-
pression, thereupon repressing viral replication. HDAC inhibitors dis-
rupt the aforementioned process, so causing LTR activation [24].
Previous studies showed that three HDAC inhibitors, including
vorinostat (Zolinza™), romidepsin (depsipeptide, FK228, FR901228),
and panobinostat (LBH589, Farydak™) have enhanced the level of
plasma viral RNA in aviremic patients on cART, indicating successful
reactivation of latent cells that unfortunately produce intact virions
[25–29]. Considering the performance of each inhibitor as far as the
plasma level of HIV is concerned, a survey summarizing and comparing
the role of each drug in treating infected patients can be of interest.
Thereby, the current paper briefly reviews and assesses the clinical
trials performed by using the HDAC inhibitors Vorinostat, Panobinostat
and Romidepsin.
2. Material and methods
After literature search, original articles were selected and included
if they met the following criteria: (1) all HIV-infected people were on
cART; (2) HDAC inhibitors included Vorinostat, or Panobinostat, or
Romidepsin; (3) the study was designed to measure the increase of
intracellular HIV-1 mRNA in CD4+ T cells of patients irrespective of
age, gender or race. We performed a search in different sources:
Medline, Scopus, DART, OpenGrey and ProQuest, without applying any
language filter, up to March 2017. Two of the authors independently
reviewed search results for irrelevant and duplicate studies and ex-
tracted data from relevant studies. Our search strategy was
((Panobinostat) OR (Farydak) OR (LBH-589) OR (LBH589) OR
(Romidepsin) OR (Istodax) OR (Vorinostat) OR (suberanilohydroxamic
acid) OR (SAHA) OR (Zolinza)) AND ((Human immunodeficiency virus)
OR (Human immune deficiency virus) OR (HIV-1) OR (human im-
munodeficiency type 1) OR (HIV-1) OR (HIV-infected) OR (Acquired
Immunodeficiency Syndrome) OR (Acquired immune deficiency syn-
drome) OR (AIDS) OR (HIV/AIDS)).
Then, we imported citations from all databases into an EndNote
library (version X6, Thomson Reuters, New York, NY, USA). In the
EndNote library, we identified duplicates among citations using the
“Find Duplicates” feature of the EndNote software. Then two of the
authors independently reviewed the title and abstract of the remainder
of the search results for irrelevant studies, that were excluded. We
collected the full text of the included articles for further screening and
data collection process.
We extracted the following data from each included publication;
first-named author, year of publication, the administration regimen of
medication, number of subjects, increases in level of intracellular HIV-1
mRNA in patients.
3. Results
We found 905 references by recruiting the search strategy in five
above-mentioned databank. We did not retrieve any new studies in the
reference lists of the main articles. After discarding duplicates, we
identified 745 publications. In a primary screening of titles and ab-
stracts, 731 articles were further excluded because of irrelevancy of the
topics. In a secondary screening of full texts, 7 studies with a total
number of 94 HIV-1 positive patients were eligible to be included in this
review (Table 1).
We found one study with 15 enrolled patients treated solely with
Panobinostat, three studies with 33 enrolled patients treated solely with
Vorinostat, and three studies with 46 enrolled patients treated with
Romidepsin.
HDAC inhibitors are anticancer agents with different structures and
some of them are currently in clinical development. The effectiveness of
Vorinostat in breaking HIV-1 latency was first evaluated by Archin and
colleagues in 2012. The study population was composed by 8 HIV-
positive patients who were on ART with plasma HIV-1 RNA less than 50
copies/ml for at least 6 months and a CD4+ T cell count higher than
300 cells/μl. The main outcomes of interest, i.e. HIV-1 RNA copy
number in resting CD4+ T cells and histone acetylation in peripheral
blood mononuclear cells, were measured at multiple time points 24 h
after the administration of 400mg Vorinostat. In each patient, a single
dose of Vorinostat increased HIV-1 RNA expression in latently infected
CD4+ T cells (mean increase: 4.8 fold); similarly, an increment in
biomarkers of cellular acetylation was observed [25]. Among these 8
patients, 5 were selected for second study by Archin et al. in 2014 with
the same inclusion criteria as the precedent study. The study covers
white males, with a mean age of 54 years. Patients received 22 cyclical
doses of Vorinostat during a period of 12–16 weeks. HIV-1 RNA in
resting CD4+ T cells increased significantly in 3 of 5 patients after dose
11 or dose 22, and the magnitude of increase in the resting CD4+ T-cell
was much declined compared with that after a single dose. In contrary
to the previous study, changes in histone acetylation were blunted. No
change was observed in viral outgrowth [30].
Elliot and colleagues administered 400mg Vorinostat daily for 2
weeks to 20 HIV-infected patients maintained on cART. At the end of
second week, CD4+ T cell-associated unspliced HIV-1 RNA enhanced
significantly in 18/20 (90%) participants (median increase: 7.4 fold).
Changes in plasma HIV-1 RNA, concentration of HIV-1 DNA, integrated
DNA and markers of T-cell activation were blunted [28].
In all of these three studies Vorinostat was safe and well tolerated,
and the presence of adverse effects (i.e., mild gastrointestinal symptoms
and transient headache) did not affect the study. Likewise Vorinostat
causes a significant increase in expression of HIV-1 RNA in CD4+ T
cells.
Previous studies on anticancer effects of HDAC inhibitors showed
that Panobinostat was at least 10-fold more potent than Vorinostat, and
might become the most potent HDAC inhibitor to be used in trials [31].
In 2014, Rasmussen et al. administered Panobinostat 20mg 3 times/
week orally for 8 weeks to 15 patients on cART. The CD4+ T cell-
associated unspliced HIV-1 RNA increased significantly (median max-
imal fold increase: 3.5) and remained elevated 1 month post-Panobi-
nostat (fold-increase 1.60; 95% CI: 1.17-2.19; p= .003). The most
common adverse effect of Panobinostat among participants was fatigue
[32].
The study performed in vitro by Wei et al. with Romidepsin showed
a greater magnitude and continuity of HIV-1 RNA expression compared
to Vorinostat, and was able to induce the release of HIV-1 virions from
latently infected cells. Intracellular pharmacology and interactions of
Romidepsin with HDAC enzymes may be responsible for such long ef-
fects, especially if compared to Vorinostat. Intramolecular disulfide
bond of Romidepsin undergoes reduction upon entering cells and turns
into free sulfhydryl groups, then interacts with the zinc ion in the active
site of different target HDAC isoforms. This inhibitory mechanism does
not apply for Vorinostat or Panobinostat [33,34]. In 2015, Sogaard
et al., administered Romidepsin 5mg/m2 intravenously 4 h per week
until 3 weeks to 6 HIV-infected patients, and found a significant in-
crease in cell associated unspliced HIV-1 RNA (median fold increase:
3.4; p= .030) [29]. Notwithstanding the use of cART, plasma HIV-1
RNA increased from<20 copies/mL at baseline to readily quantifiable
levels in 5 of 6 patients who received Romidepsin (range: 46–103 co-
pies/mL following the second infusion, p= .040). The most frequently
reported adverse effects of Romidepsin were gastrointestinal symptoms
(i.e., nausea, increased bowel sounds and abdominal pain). Albeit in-
creasing in virus transcription has been observed, no changes were
observed in amount of latent reservoirs in vivo [28,29].
4. Discussion
LRA are interesting drugs for pursuing the shock and kill strategy,
aimed at eradicating HIV infection. Indeed, in order to kill infected cells
that do not produce spontaneously the virus, the immune system has to
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recognize viral antigens, and LRA are able to unmask latently infected
cells, allowing the presentation of viral peptides on MHC class I. In vitro
studies showed that Romidepsin is the most potent LRA tested, in-
troducing it as a “prototype” drug that can be used as a reference for
developing and testing new LRA.
Among studies in HIV-infected patients, one failed to show any
significant variation of plasma viral load in almost half of patients
treated with Romidepsin and Vacc-4 x in combination therapy [35,36].
The following reasons may justify ineffectiveness of the LRA in this
study: first, stimulation of HIV-1 expression did not lead to the death of
the cells. Secondly, these drugs are incapable to cross obstacles such as
blood brain barrier. Moreover, neither ART nor LRA are reluctant to
restore the impaired cytotoxic activity of CD8+ T cells. Likewise, fol-
lowing the “shock” strategy, a boosted immune system is required to
eliminate HIV-infected cells [36,37]. Thus, a more complex strategy
could be envisaged that likely could include molecules able to activate
immune responses, such as cytokines. Another study by Tapia. et. al
[37] that may support the results of the in vitro studies, showed re-
ductions in total HIV DNA after using Vacc-4 x followed by Romidepsin
administration. Also in this case, it is likely that a more sophisticated
combination approach may be needed to effectively eliminate the pool
of latent reservoirs.
Vorinostat affects gene regulation by several mechanisms consistent
with ability of HDAC enzymes to target both histones and non-histone
proteins, including HDAC1, signaling mediators and chaperones [38].
This drug could increase HIV-RNA significantly in human studies, si-
milar to its effects during in vitro trials [25,28,30]. Panobinostat as a
highly potent HDAC inhibitor had been previously used in treatment of
multiple myeloma. Therapeutic concentrations of Panobinostat induce
viral production in latently infected cells in vitro [36].
Overall, based on the current studies, it is pivotal to consider la-
tently infected cells as a crucial target of the strategy to reduce the size
of HIV reservoir. As a future investigation, it is worth to study innate
immune activity, which, based on a work by Olesen et al. [39], can
modify the effects of LRAs on quiescent cells.
5. Conclusions
To date, HDAC inhibitors have shown the proof-of-concept, inter-
fering with persistent infection. Molecules like vorinostat, panobino-
stat, or romidepsin have yet to be tested in patients with persistently
low CD4+ counts. They seem to be effective in those on stable ART for
long time, and likely could be utilized in addition to ART. In any case,
more investigation is needed to better understand other major aspects
of the impact of HDAC inhibitors on the strategy required to eradicate
HIV.
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